Cipla Patalganga facility gets EIR from USFDA

"Following the inspection by the United States Food and Drug Administration (USFDA) at the Patalganga manufacturing facility of the company from November 4, 2019, to November 13, 2019, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection," the homegrown pharma major said in a filing to the BSE.

New Delhi: Cipla on Monday announced the closure of inspection by the US health regulator at its Patalganga manufacturing facility in Maharashtra.

Also Read: No Relief: DOP Rejects Review Petition By CIPLA Challenging NPPA Price Fixation

"Following the inspection by the United States Food and Drug Administration (USFDA) at the Patalganga manufacturing facility of the company from November 4, 2019, to November 13, 2019, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection," the homegrown pharma major said in a filing to the BSE.

Headquartered in Mumbai, Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions. The company sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products, including Escitalopram (anti-depressant), Lamivudine and Fluticasone propionate. They are the world's largest manufacturer of antiretroviral drugs.

Also Read: SETBACK: Delhi HC Restricts Cipla From Launching Generic Version Of Apixaban